Harbour BioMed’s wholly-owned subsidiary Nona Biosciences announced that it has entered into an exclusive license agreement with Pfizer for the global clinical development and commercialisation of HBM9033, Nona’s MSLN-targeted antibody-drug conjugate (ADC). MSLN is a tumor-associated antigen upregulated in various solid tumors. Nona will receive up to US$53M in upfront and near-term payments, with potential for payments up to US$1.05B contingent on achievement of development and commercial milestones.
In July 2023, Pfizer reached another large value deal with Samsung Biologics worth US$897M for Samsung’s manufacture of biosimilars.